ARCHIVES

Novel Agents Promise Relief From Hematologic Side Effects

This article is from The Cancer Letter archive.

Vol. 24 No. 7 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

November 28, 2014

Funding Opportunities

February 28, 2003

Scientific Opportunity Should Guide Fund Allocation, House Says

August 4, 1995

Brawley: CMS Got it Right in Lung Cancer Screening Decision

November 14, 2014

Cyclamate Review Committee Starts Survey; Inventor Castigates NCI

September 12, 1975

FDA Relies on Importation, Fast Approval, and Early Reporting to Combat Drug Shortages

February 24, 2012